Last updated: July 31, 2026
Benazepril hydrochloride is a mature, low-cost ACE inhibitor with minimal remaining exclusivity, extensive generic competition, and declining commercial relevance as a branded product. The U.S. market is supplied primarily through generic tablets, while the branded product Lotensin has been discontinued or commercially inactive in many channels. Financial value is concentrated in manufacturing efficiency, pharmacy contracts, combination products, and selected international markets rather than in patent-based pricing power.
What is the current FDA status of benazepril hydrochloride?
Benazepril hydrochloride is an FDA-approved angiotensin-converting enzyme inhibitor used to treat hypertension. The active metabolite, benazeprilat, inhibits formation of angiotensin II and reduces aldosterone secretion.
The FDA approved Lotensin, the original benazepril hydrochloride product, in 1991 for hypertension in adults. The product is available in 5 mg, 10 mg, 20 mg, and 40 mg tablets. Benazepril hydrochloride is also marketed in combination with hydrochlorothiazide under the Lotensin HCT brand and as generic combination tablets.[1]
| Product |
Active ingredient |
Dosage forms |
Primary use |
U.S. commercial status |
| Lotensin |
Benazepril hydrochloride |
5, 10, 20, 40 mg tablets |
Hypertension |
Legacy brand; limited or discontinued commercial presence |
| Generic benazepril hydrochloride |
Benazepril hydrochloride |
5, 10, 20, 40 mg tablets |
Hypertension |
Widely marketed |
| Lotensin HCT |
Benazepril hydrochloride and hydrochlorothiazide |
Multiple strengths |
Hypertension |
Legacy brand; generic competition |
| Generic benazepril hydrochloride/HCTZ |
Benazepril hydrochloride plus hydrochlorothiazide |
Multiple strengths |
Hypertension |
Generic availability |
The product is a small-molecule chemical drug. Biosimilar regulation does not apply. Competitive risk comes from generic manufacturers, therapeutic substitutes, and fixed-dose antihypertensive combinations.
When did benazepril hydrochloride lose exclusivity?
Benazepril hydrochloride lost meaningful U.S. market exclusivity many years ago. The original product was approved in 1991, and generic entry followed after expiration of the relevant compound and regulatory exclusivity protections.
The current market has no commercially important period of branded exclusivity. FDA Orange Book listings for benazepril products are relevant mainly to abbreviated new drug application, or ANDA, status and product-level patent information. The active ingredient is now treated as an established generic molecule rather than a protected innovation.[2]
Benazepril patent expiration timeline
| Event |
Approximate timing |
Commercial effect |
| Original benazepril patent filings |
Early 1980s |
Created compound and pharmaceutical composition protection |
| U.S. approval of Lotensin |
1991 |
Began branded commercialization |
| Original compound exclusivity period |
Expired before or around the early generic era |
Removed the principal barrier to ANDA entry |
| Generic benazepril approvals |
Late 1990s to early 2000s |
Initiated price competition |
| Current market |
2026 |
Mature multi-source generic market with limited patent leverage |
The exact patent term depends on the specific patent, filing date, patent-term adjustment, and any applicable regulatory extension. The original compound patent family is no longer a practical barrier to generic entry. Later patents, where listed for particular products, do not recreate broad exclusivity for benazepril hydrochloride as an active ingredient.
What patents protect benazepril hydrochloride?
The original benazepril patent estate covered the compound and related pharmaceutical compositions. The historic U.S. patent commonly associated with benazepril is U.S. Patent No. 4,410,520, assigned to Ciba-Geigy Corporation and directed to benazepril-related compounds and compositions.[3]
The commercial significance of that patent has ended. Current value does not arise from the original compound claim because generic manufacturers have been able to market benazepril hydrochloride for years.
Patent categories relevant to benazepril
| Patent category |
Historic or current relevance |
Generic-entry impact |
| Compound patents |
Core benazepril molecule |
Expired; no current broad barrier |
| Salt and composition patents |
Benazepril hydrochloride formulation and pharmaceutical compositions |
Generally expired or commercially weak |
| Tablet formulation patents |
Excipients, dissolution, stability, or manufacturing attributes |
Usually narrow and avoidable |
| Combination-product patents |
Benazepril plus hydrochlorothiazide |
Relevant only to the specific combination |
| Method-of-use patents |
Treatment of hypertension or related conditions |
Limited value where claims overlap the approved generic indication |
| Manufacturing patents |
Processes, intermediates, crystallization, or impurity control |
May protect a supplier’s process without blocking alternative manufacture |
A generic manufacturer can generally pursue a conventional immediate-release tablet through the ANDA pathway if it demonstrates pharmaceutical equivalence and bioequivalence to the reference product. A formulation or process patent could require a Paragraph IV certification or a design-around, but no broad current patent barrier is associated with the molecule.
How many patents cover benazepril hydrochloride?
No meaningful number of active, broad U.S. patents protects the benazepril hydrochloride molecule itself. The historic compound estate has expired. Any currently relevant patents would generally be product-specific, formulation-specific, process-specific, or associated with a combination product.
Patent counts should therefore be separated into three categories:
- Expired patents covering the active ingredient or original product.
- Potentially active patents covering a particular formulation, manufacturing process, or combination.
- Patent records listed for individual products in the Orange Book.
A raw count of patent documents can overstate competitive protection because continuation patents, foreign counterparts, expired patents, and narrow process claims may not prevent an ANDA launch.
What is the Orange Book status of benazepril hydrochloride?
The Orange Book identifies approved drug products and relevant patent and exclusivity information. Benazepril hydrochloride has long been subject to generic substitution through ANDA-approved products. The relevant reference product history is associated with Lotensin and, for the combination product, Lotensin HCT.[2]
The practical Orange Book position is:
- No current new chemical entity exclusivity protects benazepril hydrochloride.
- No active branded exclusivity supports premium pricing for Lotensin.
- Generic tablets are approved through ANDAs.
- Product-level patent entries, if present, must be assessed by strength, dosage form, and formulation.
- Combination-product listings should not be treated as patents covering benazepril monotherapy.
The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations remains the controlling source for current reference-listed drug, therapeutic-equivalence, patent, and exclusivity records.
Which companies market generic benazepril hydrochloride?
Generic benazepril hydrochloride has been marketed by multiple U.S. suppliers over time. The supplier roster can change because manufacturers withdraw products, transfer ANDAs, or use contract manufacturing arrangements. Historical and current participants have included major generic companies such as Sandoz, Teva, Mylan or Viatris, and other ANDA holders.[2]
The market is not controlled by one durable branded franchise. Distribution commonly occurs through:
- National retail pharmacy chains.
- Wholesalers.
- Medicaid and commercial-plan formularies.
- Mail-order pharmacies.
- Institutional and hospital purchasing groups.
- Private-label or authorized-generic channels.
Manufacturer economics depend more on supply reliability and contract access than on product differentiation.
How strong is the benazepril hydrochloride patent estate?
The patent estate is weak from a commercial-exclusivity perspective.
| Factor |
Assessment |
| Core compound protection |
Expired |
| New chemical entity exclusivity |
Expired |
| Branded pricing power |
Minimal |
| Generic barriers |
Low |
| Formulation differentiation |
Limited for standard immediate-release tablets |
| Manufacturing complexity |
Moderate but manageable |
| Litigation leverage |
Low |
| Biosimilar risk |
Not applicable |
| Substitution risk |
High |
Benazepril is a conventional small molecule administered as an immediate-release oral tablet. It does not require a complex delivery device, sterile manufacturing, biologic production platform, or cold-chain infrastructure. Those characteristics reduce technical barriers to entry.
Manufacturing still requires control of impurity profiles, assay, content uniformity, stability, dissolution, and the quality of the benazepril hydrochloride active pharmaceutical ingredient. These requirements create compliance costs, but they do not create durable market exclusivity.
What generic entry risks exist for benazepril hydrochloride?
Generic entry risk is already realized rather than prospective. Multiple-source competition has reduced prices and removed most branded demand.
A new entrant would face:
- Low average selling prices.
- Established supplier relationships.
- Pharmacy-benefit-manager and wholesaler contracting.
- Limited ability to differentiate a standard tablet.
- Potentially small unit volumes relative to manufacturing and regulatory costs.
- Exposure to commodity-style price competition.
The principal commercial risk is not a sudden generic launch against a protected product. It is continued erosion of gross margin, supply disruptions, and loss of preferred formulary position.
What Paragraph IV challenges affected benazepril hydrochloride?
Paragraph IV litigation was relevant during the transition from Lotensin exclusivity to generic competition. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.
For a mature product such as benazepril hydrochloride, historic Paragraph IV activity has limited current financial relevance because the core patent estate has expired and generic products are already established. The principal modern question is whether a new patent is listed for a specific combination, formulation, or later product. Such a challenge would not ordinarily restore exclusivity for standard benazepril hydrochloride tablets.
What patent litigation affects benazepril hydrochloride?
There is no current litigation landscape comparable to the patent disputes surrounding high-value branded drugs. Benazepril litigation has historically been associated with generic entry, patent certifications, product liability, or commercial disputes rather than with a continuing blockade of the molecule.
For diligence purposes, litigation should be screened separately for:
- Lotensin and Lotensin HCT patent disputes.
- ANDA litigation involving specific generic applicants.
- Product liability claims related to ACE-inhibitor adverse events.
- Manufacturing and supply agreements.
- International patent disputes involving combination products.
The absence of a major active U.S. patent dispute is consistent with the product’s mature generic status.
What formulations are protected by benazepril patents?
The commercially important formulation is the immediate-release oral tablet. Historic patents covered benazepril compounds and pharmaceutical compositions. Current formulation protection, if any, would likely concern a narrow claim involving excipients, stability, particle characteristics, dissolution, or a specific fixed-dose combination.
Benazepril hydrochloride does not have a commercially dominant extended-release, transdermal, implantable, or specialty-delivery formulation. That limits opportunities to shift demand into a protected formulation segment.
Benazepril hydrochloride/hydrochlorothiazide is commercially distinct from monotherapy. A patent or regulatory record associated with the combination does not automatically block generic benazepril hydrochloride alone.
How does benazepril compare with competing ACE inhibitors?
Benazepril competes with lisinopril, enalapril, ramipril, quinapril, perindopril, and captopril. It also competes with angiotensin II receptor blockers, calcium-channel blockers, thiazide diuretics, and newer combination therapies.
| Drug |
Market status |
Commercial position |
| Benazepril |
Mature generic |
Low-cost, established |
| Lisinopril |
Mature generic |
Typically stronger volume and prescription visibility |
| Enalapril |
Mature generic |
Established low-cost alternative |
| Ramipril |
Mature generic |
Used in hypertension and cardiovascular-risk management |
| Losartan |
Mature generic ARB |
Major therapeutic substitute |
| Amlodipine |
Mature generic calcium-channel blocker |
High-volume substitute |
| Benazepril/HCTZ |
Generic combination |
Niche relative to monotherapy and leading combinations |
Lisinopril generally has greater prescription-scale visibility in the U.S. generic antihypertensive market. Benazepril retains clinical use where prescribers prefer its pharmacologic profile or where patients remain stable on therapy, but switching pressure is high because therapeutic alternatives are abundant.
What is the financial trajectory for benazepril hydrochloride?
The financial trajectory follows the standard lifecycle of an oral small-molecule medicine:
- Branded launch and physician adoption after FDA approval.
- Peak value during the protected brand period.
- Rapid revenue decline after generic entry.
- Long-term stabilization as a low-price generic.
- Margin pressure from additional suppliers and purchasing consolidation.
Public companies generally do not report benazepril hydrochloride revenue as a standalone line item. It is usually included within broader generic-pharmaceutical sales. As a result, precise product-level revenue, margin, and market-share estimates require commercial prescription or sales datasets rather than company filings.
Revenue exposure by business model
| Business model |
Benazepril exposure |
| Original branded manufacturer |
Very limited or discontinued |
| Large generic manufacturer |
Low revenue per unit; potentially useful portfolio product |
| API supplier |
Volume-driven, price-sensitive demand |
| Contract manufacturer |
Opportunity depends on customer contracts and capacity |
| Specialty pharmaceutical company |
Limited strategic fit |
| Licensing platform |
Low value unless tied to a differentiated combination or delivery system |
The molecule can generate stable cash flow for a manufacturer with low-cost API access and efficient tablet production. It is unlikely to support meaningful premium pricing, a high-value licensing transaction, or a standalone public-company growth thesis.
What licensing deals involve benazepril hydrochloride?
The original commercial rights were associated with Ciba-Geigy, which later became part of Novartis. The original brand and historical development rights no longer provide a meaningful exclusivity-based licensing opportunity in the United States.
Current licensing value would most likely involve:
- Regional commercialization rights.
- Supply of finished-dose tablets.
- API sourcing.
- Fixed-dose combinations.
- Private-label distribution.
- Portfolio transactions involving multiple generic products.
A standalone license for ordinary benazepril hydrochloride tablets would have limited negotiating leverage because equivalent generic products are widely available.
What geographic markets remain commercially relevant?
Benazepril hydrochloride has broader relevance outside the United States, but international value remains generic and price-sensitive.
Key considerations include:
- Regulatory approval and market authorization in each country.
- Local substitution rules.
- National reimbursement pricing.
- Government tenders.
- API sourcing requirements.
- Local manufacturing or localization policies.
- Brand persistence in markets where physicians continue prescribing legacy products.
The United States is a mature multi-source market. Emerging-market demand may provide volume growth, but lower prices and tender competition can limit profitability. In some countries, the original brand or a branded generic may retain recognition, but that does not equate to strong patent protection.
What manufacturing and intellectual-property barriers remain?
The principal barriers are operational rather than patent-based. A manufacturer must maintain compliant API sourcing, validated processes, stability data, quality systems, and reliable supply. Benazepril hydrochloride is more manageable than complex biologics or specialized delivery products because it is an oral small molecule with conventional tablet manufacturing.
Manufacturing risks include:
- API impurity and degradation control.
- Supplier concentration.
- Batch failures.
- Regulatory observations.
- Product recalls.
- Shortages caused by low-margin production.
- Competition from lower-cost overseas manufacturers.
These factors can temporarily improve pricing during a shortage, but they do not create durable intellectual-property value.
What are the likely generic launch scenarios?
For standard benazepril hydrochloride tablets, the relevant launch scenario is continued generic supply rather than a future first generic event.
| Scenario |
Probability profile |
Financial effect |
| Stable multi-source supply |
Base case |
Low prices and modest recurring volume |
| Supplier withdrawal |
Periodic risk |
Temporary share and price opportunity for remaining suppliers |
| API disruption |
Periodic risk |
Potential shortages and higher procurement costs |
| New formulation launch |
Low |
Limited upside unless clinically differentiated |
| Branded re-entry |
Low |
Difficult against generic substitution |
| Combination-product expansion |
Moderate but niche |
Incremental portfolio value |
A manufacturer entering today would need a low-cost supply model, reliable distribution, or a contract already secured. Patent clearance is unlikely to be the primary obstacle.
Key Takeaways
- Benazepril hydrochloride is an FDA-approved, mature ACE inhibitor marketed mainly as a generic tablet.
- The original Lotensin exclusivity period ended long ago.
- The historic compound patent estate, including U.S. Patent No. 4,410,520, no longer creates a broad market barrier.
- Biosimilar risk does not apply because benazepril hydrochloride is a small molecule.
- Generic competition, therapeutic substitution, and payer contracting define the market.
- Product-level financial data are generally not disclosed separately by public manufacturers.
- Commercial value is concentrated in low-cost production, API supply, distribution access, and combination products.
- The strongest risks are price erosion, supplier withdrawal, regulatory compliance costs, and manufacturing disruption.
- A standalone benazepril license or branded relaunch would have limited strategic value absent a differentiated formulation or regional market opportunity.
FAQs
Is benazepril hydrochloride still under patent?
No broad, commercially meaningful patent protects the benazepril hydrochloride molecule in the current U.S. market. Historic compound and composition patents have expired.
Is Lotensin still sold in the United States?
Lotensin is a legacy branded product with limited or discontinued commercial significance. Generic benazepril hydrochloride supplies the U.S. market.
Can a generic company launch benazepril without a Paragraph IV challenge?
For a standard product with no blocking unexpired patent, an ANDA applicant may rely on the applicable certification pathway. A Paragraph IV certification is relevant only if a listed unexpired patent must be challenged.
Does benazepril hydrochloride have a biosimilar competitor?
No. Biosimilars apply to biological products. Benazepril hydrochloride competes with chemically equivalent generics.
Is benazepril hydrochloride a good licensing asset?
As a standalone generic tablet, it has limited licensing value. The stronger opportunities are regional distribution, contract supply, API manufacturing, and differentiated fixed-dose combinations.
References
-
U.S. Food and Drug Administration. (1991). Lotensin (benazepril hydrochloride) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2026). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Patent and Trademark Office. (1983). U.S. Patent No. 4,410,520: Benazepril compounds and pharmaceutical compositions. U.S. Department of Commerce.
